Troy B Puga, Tanner Haechten, Vincent Dieu, McKenna W Box, Kyle P O'Connor, John T Riehl
{"title":"胰高血糖素样肽-1受体激动剂（GLP-1A）和全髋关节置换术（THA）患者的结局：一项系统综述和荟萃分析。","authors":"Troy B Puga, Tanner Haechten, Vincent Dieu, McKenna W Box, Kyle P O'Connor, John T Riehl","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1a) medications have rapidly grown in popularity, however, their effects on the outcomes of Total Hip Arthroplasty (THA) remain largely unclear. The objective of this systematic review and meta-analysis is to evaluate the outcomes of patients undergoing THA and using a GLP-1a medication.</p><p><strong>Methods: </strong>A search was conducted across six databases. The search used a combination of keywords and Medical Subject Heading (MeSH) terms. Titles and abstracts were screened for eligibility for inclusion criteria. Full texts were screened and included if they met eligibility criteria. Demographics and results of the studies were extracted from included articles. Meta-analysis was conducted.</p><p><strong>Results: </strong>In this systematic review and metaanalysis, 10 studies met final inclusion criteria, and nine studies met inclusion for meta-analysis. Patients using GLP-1a medications in the setting of THA to those not using GLP-1a medications found a statistically significant decrease in the odds of readmission (OR: 0.81 (95% CI: 0.70-0.93); P<0.001), and no significant difference in the odds of surgical site infections (OR: 0.85 (95% CI: 0.601.20); P=0.36). At 90 days, there was no significant difference in prosthetic joint infections (OR: 1.19 (95% CI: 0.92-1.54); P=0.18), periprosthetic fractures (OR: 1.17 (95% CI: 0.82-1.68); P=0.40), and surgical or medical complications (OR: 0.84 (95% CI: 0.68-1.03); P=0.10) (Figures 4-6). At 2 years, there was no significant difference in periprosthetic fractures (OR: 0.99 (95% CI: 0.531.84); P=0.97) or prosthetic joint infections (OR: 0.98 (95% CI: 0.67-1.44); P=0.93).</p><p><strong>Conclusion: </strong>The findings of this study suggest that patients using GLP-1a medications while undergoing THA had reduced 90 day readmission rates, with equivalent rates of SSI, medical and surgical complications, PJI at 90 days and 2 years, and periprosthetic fracture 90 days and 2 years when compared with those not using GLP-1a medications. GLP-1a medications may be safely used in patients undergoing THA.</p><p><strong>Level of evidence: </strong>III.</p>","PeriodicalId":94233,"journal":{"name":"The Iowa orthopaedic journal","volume":"46 1","pages":"55-64"},"PeriodicalIF":0.0000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13389273/pdf/","citationCount":"0","resultStr":"{\"title\":\"Outcomes of Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1A) and Patients Undergoing Total Hip Arthroplasty (THA): A Systematic Review and Meta-Analysis.\",\"authors\":\"Troy B Puga, Tanner Haechten, Vincent Dieu, McKenna W Box, Kyle P O'Connor, John T Riehl\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1a) medications have rapidly grown in popularity, however, their effects on the outcomes of Total Hip Arthroplasty (THA) remain largely unclear. The objective of this systematic review and meta-analysis is to evaluate the outcomes of patients undergoing THA and using a GLP-1a medication.</p><p><strong>Methods: </strong>A search was conducted across six databases. The search used a combination of keywords and Medical Subject Heading (MeSH) terms. Titles and abstracts were screened for eligibility for inclusion criteria. Full texts were screened and included if they met eligibility criteria. Demographics and results of the studies were extracted from included articles. Meta-analysis was conducted.</p><p><strong>Results: </strong>In this systematic review and metaanalysis, 10 studies met final inclusion criteria, and nine studies met inclusion for meta-analysis. Patients using GLP-1a medications in the setting of THA to those not using GLP-1a medications found a statistically significant decrease in the odds of readmission (OR: 0.81 (95% CI: 0.70-0.93); P<0.001), and no significant difference in the odds of surgical site infections (OR: 0.85 (95% CI: 0.601.20); P=0.36). At 90 days, there was no significant difference in prosthetic joint infections (OR: 1.19 (95% CI: 0.92-1.54); P=0.18), periprosthetic fractures (OR: 1.17 (95% CI: 0.82-1.68); P=0.40), and surgical or medical complications (OR: 0.84 (95% CI: 0.68-1.03); P=0.10) (Figures 4-6). At 2 years, there was no significant difference in periprosthetic fractures (OR: 0.99 (95% CI: 0.531.84); P=0.97) or prosthetic joint infections (OR: 0.98 (95% CI: 0.67-1.44); P=0.93).</p><p><strong>Conclusion: </strong>The findings of this study suggest that patients using GLP-1a medications while undergoing THA had reduced 90 day readmission rates, with equivalent rates of SSI, medical and surgical complications, PJI at 90 days and 2 years, and periprosthetic fracture 90 days and 2 years when compared with those not using GLP-1a medications. GLP-1a medications may be safely used in patients undergoing THA.</p><p><strong>Level of evidence: </strong>III.</p>\",\"PeriodicalId\":94233,\"journal\":{\"name\":\"The Iowa orthopaedic journal\",\"volume\":\"46 1\",\"pages\":\"55-64\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2026-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13389273/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Iowa orthopaedic journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Iowa orthopaedic journal","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Outcomes of Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1A) and Patients Undergoing Total Hip Arthroplasty (THA): A Systematic Review and Meta-Analysis.
Background: Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1a) medications have rapidly grown in popularity, however, their effects on the outcomes of Total Hip Arthroplasty (THA) remain largely unclear. The objective of this systematic review and meta-analysis is to evaluate the outcomes of patients undergoing THA and using a GLP-1a medication.
Methods: A search was conducted across six databases. The search used a combination of keywords and Medical Subject Heading (MeSH) terms. Titles and abstracts were screened for eligibility for inclusion criteria. Full texts were screened and included if they met eligibility criteria. Demographics and results of the studies were extracted from included articles. Meta-analysis was conducted.
Results: In this systematic review and metaanalysis, 10 studies met final inclusion criteria, and nine studies met inclusion for meta-analysis. Patients using GLP-1a medications in the setting of THA to those not using GLP-1a medications found a statistically significant decrease in the odds of readmission (OR: 0.81 (95% CI: 0.70-0.93); P<0.001), and no significant difference in the odds of surgical site infections (OR: 0.85 (95% CI: 0.601.20); P=0.36). At 90 days, there was no significant difference in prosthetic joint infections (OR: 1.19 (95% CI: 0.92-1.54); P=0.18), periprosthetic fractures (OR: 1.17 (95% CI: 0.82-1.68); P=0.40), and surgical or medical complications (OR: 0.84 (95% CI: 0.68-1.03); P=0.10) (Figures 4-6). At 2 years, there was no significant difference in periprosthetic fractures (OR: 0.99 (95% CI: 0.531.84); P=0.97) or prosthetic joint infections (OR: 0.98 (95% CI: 0.67-1.44); P=0.93).
Conclusion: The findings of this study suggest that patients using GLP-1a medications while undergoing THA had reduced 90 day readmission rates, with equivalent rates of SSI, medical and surgical complications, PJI at 90 days and 2 years, and periprosthetic fracture 90 days and 2 years when compared with those not using GLP-1a medications. GLP-1a medications may be safely used in patients undergoing THA.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
